aft pharmaceuticals
AFT lifts profit guidance after weak start
Hikma Pharmaceutical’s first sale of Maxigesic IV in the US delivers boost for AFT Pharmaceuticals AFT Pharmaceuticals – the owner of the Maxigesic ibuprofen/paracetamol combination drug – has raised its …
AFT sees 24% hike in sales
Flagship Maxigesic products and Australian OTC business contribute the most to latest half yearly results Maxigesic manufacturer AFT Pharmaceuticals has reported higher bottom-line profit and revenue after continued robust demand …
AFT launches on Amazon
Deal with Sell Global moves Kiwi battler onto US and Australian Amazon sites Feisty New Zealand outfit AFT Pharmaceuticals has launched own-branded online stores on the US and Australian Amazon …
AFT to pay first dividend as income soars 20%
Kiwi Maxigesic owner posts $NZD20m profit boosted by licensing income AFT Pharmaceuticals, the New Zealand-headquartered outfit best known for its Maxigesic ibuprofen/paracetamol combination, will pay its first dividend in its …
“Lumpy” licensing lag hits AFT profits
Kiwi pharmaco behind Maxigesic sees net profits down 2/3 year-on-year but leadership remains upbeat about the future Lower licencing income and increased growth in spending were factors which saw the …
Third time lucky for AFT
NZ company wins appeal in Maxigesic comparative advertising case AFT Pharmaceuticals has been victorious in its marathon legal battle with Nuromol producer Reckitt Benckiser to declare in advertising that its …
AFT reports 32% rise in gross profit
The pharmaceutical company has also seen a 16% growth in revenue, as it launches Maxigesic across several countries AFT Pharmaceuticals has announced its full-year audited financial results for the year …
Sandomigran update: packs reach wholesalers
AFT Pharmaceuticals has issued an update on the availability of Sandomigran, which has experienced accessibility issues of late. Due to packaging problems at the packing site in Europe a backlog …